French artificial intelligence (AI) startup Iktos and drug discovery firm Facio Therapies have announced they are collaborating to design treatment for the skeletal muscle wasting condition facioscapulohumeral dystrophy (FSHD).
Under the agreement, Iktos will apply its de novo ligand and structure-based generative modelling AI technologies in one of Facio’s drug discovery programmes.
The...
